IM Cannabis

IMCC

Market cap $5.84M

TORONTO and GLIL YAM, Israel, Jan. 26, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced that it has raised a total of US$2,171,660.40 in debt financings from an arm's length third party (the "Lender") in order to manage the Company's current liquidity requirements. First Note Pursuant to a note purchase agreement between the Company and Lender dated January 7, 2026 (the "First Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$1,538,749, after application of an original issuance discount of 10% (the "First Note").

TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025.

TORONTO and GLIL YAM, Israel , Dec. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg. Mr. Levi has over 15 years of experience in finance and controlling roles, including serving as Chief Financial Officer of Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc and as Controller of SciSparc Ltd.

TORONTO and GLIL YAM, Israel , Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated.

TORONTO and GLIL YAM, Israel , Nov. 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third quarter 2025 ended September 30, 2025, on Thursday, November 13, 2025, before the market opens. About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets.

TORONTO and GLIL YAM, Israel , Oct. 29, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading international medical cannabis company with operations in Israel and Germany, today announced that Uri Birenberg, the Company's Chief Financial Officer, will be stepping down from his role  for personal reasons. Mr. Birenberg is expected to continue serving as Chief Financial Officer until January 5, 2026, or such earlier date as may be determined by the Company, and will assist in a structured transition process until a successor is appointed.

The cannabis industry continues to evolve as investors prepare for potential U.S. federal reform and international market expansion. Despite short-term volatility, global demand for both medical and recreational cannabis is increasing. Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes. However, navigating this emerging sector requires careful attention to fundamentals, technical analysis, and disciplined risk management. Traders should focus on companies that show financial stability, market expansion, and consistent revenue growth before the next wave of legalization news.

TORONTO and GLIL YAM, Israel , Oct. 23, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a pioneering quantum computing bio data company ("The Target Company") for aggregate consideration of up to $54 million. The Target Company specializes in utilizing quantum computing principles to store, manipulate, and analyze BIO data more efficiently than current technologies, offering groundbreaking advancements in biological data processing and analytics.

TORONTO and GLIL YAM, Israel , Sept. 16, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the following changes to its Board of Directors (the "Board").

TORONTO and GLIL YAM, Israel , Sept. 5, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced that it received notice from Nasdaq on September 4, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000.